Search the Newsreel

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing a Phase III study of IFx in Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates. The company aims to address …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway

TuHURA Bios reported its Q2 2026 results, showing $1.0 million in cash and cash equivalents and R&D expenses of $6.6 million. The company secured a new $50 million term credit facility from its largest shareholder, extending its cash runway into 2028. This credit facility …

TuHURA Biosciences (HURA) Earnings Date and Reports 2026

HURA Q2'26 Earnings: revenue estimate is 0 USD

TuHURA Biosciences, Inc. (HURA) is scheduled to release its Q2'26 earnings on August 14. The company anticipates a revenue of $0 and an EPS of ($0.15) for the quarter. This article provides a brief overview of the upcoming earnings report and historical revenue and …

TuHURA Biosciences Inc (HURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of TuHURA Biosciences Inc (HURA), including support and resistance levels, indicator values, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, alongside different moving averages, to give a comprehensive overview of the stock's current …

TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday

TuHURA Biosciences (HURA) is scheduled to release its Q2 2026 earnings on Thursday, August 13th, with analysts forecasting a loss of $0.1533 per share. The company previously missed consensus estimates in Q1 2026, reporting a loss of $0.13 per share. HURA currently holds a …

TuHURA Biosciences Inc (HURA) Institutional Confidence

This article provides an overview of TuHURA Biosciences Inc (HURA) focusing on its institutional confidence, represented by significant shareholder activity. It lists key shareholders including individuals like Vijay Patel and Matthew Nachtrab, and institutional investors such as BlackRock and Geode Capital Management, along with …

TuHURA Biosciences Inc (HURA) Cash Flow

This article provides a detailed cash flow statement for TuHURA Biosciences Inc (HURA), including quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes and defines key cash flow metrics. The report aims to help users …

TuHURA Biosciences Inc (HURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article "TuHURA Biosciences Inc (HURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution" states that relevant revenue breakdown data for TuHURA Biosciences Inc (HURA) has not yet been disclosed by the company. Despite the title suggesting a breakdown, the content explicitly mentions …

HURA|TuHURA Biosciences Inc|Price:2.110|Chg%:-0.040

This TradingKey article provides an overview of TuHURA Biosciences Inc. (HURA) stock, which closed at $2.110, down 1.86%. The company does not currently have a stock score available due to insufficient data, and relevant data for peer comparison have not been disclosed. The article …

TuHURA Biosciences Inc HURA Income Statement

The article presents the quarterly and annual income statements for TuHURA Biosciences Inc (HURA), offering a detailed financial overview for investors. It includes key metrics such as operating expenses, R&D expenses, depreciation, operating profit, non-operating income/expenses, and net income figures over several fiscal years …

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Moderate Buy" from Analysts

TuHURA Biosciences (NASDAQ:HURA) has received an average rating of "Moderate Buy" from analysts, with five out of six firms issuing a buy rating and one a sell. The average 12-month price target for the stock is $9.00. Despite this, the company reported a quarterly …

TuHURA Biosciences to Present at Canaccord Genuity Conference

TuHURA Biosciences CEO, Dr. James A. Bianco, will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, to discuss the company's advancements in cancer immunotherapy. The company is progressing with a Phase 3 trial for IFx-2.0, a Phase 1b trial …

TuHURA Biosciences (HURA) Proxy filing Summary

TuHURA Biosciences (HURA) has scheduled its annual meeting for August 18, 2026, to be held virtually, where shareholders will vote on several key matters. These include the election of six directors, the approval of issuing 1,878,287 shares of common stock, and advisory votes on …

TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 1.3% - Time to Sell?

TuHURA Biosciences (NASDAQ:HURA) saw its stock price fall by 1.3% to $2.21, trading well below its average volume. The company remains unprofitable, missing recent earnings estimates with a loss of $0.13 per share against an expected $0.12 loss. While analyst sentiment is mixed but …